Stock Track | Day One Biopharmaceuticals Soars 5% on Promising OJEMDA Data for Pediatric Brain Cancer

Stock Track

Nov 10, 2025

Day One Biopharmaceuticals Inc. (DAWN) saw its stock soar by 5.04% in pre-market trading on Monday, following the announcement of new data for its lead product candidate, OJEMDA™ (tovorafenib). The company revealed that updated results from its Phase 2 FIREFLY-1 trial will be presented at the upcoming Society for Neuro-Oncology (SNO) Annual Meeting, showcasing the drug's potential in treating pediatric low-grade glioma (pLGG).

The oral presentation, scheduled for November 23, 2025, will feature more than 36 months of follow-up data from the FIREFLY-1 trial. This study evaluates tovorafenib as a once-weekly oral monotherapy in patients aged 6 months to 25 years with relapsed or progressive pLGG harboring a known activating BRAF alteration. The data is expected to demonstrate durable responses and clinical stability off treatment, as well as newly disclosed treatment-free interval information.

Investors are reacting positively to this news, as it suggests OJEMDA's potential efficacy in treating this challenging form of pediatric brain cancer. The durability of responses and the possibility of treatment-free intervals are particularly encouraging, as they could significantly improve the quality of life for young patients. As Day One Biopharmaceuticals continues to advance its pipeline, the market appears optimistic about the company's prospects in the pediatric oncology space.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1141167308"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1141167308\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1141167308?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 23:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141167308","market":"hk","top_or_hot":-1,"title":"Stock Track | Day One Biopharmaceuticals Soars 5% on Promising OJEMDA Data for Pediatric Brain Cancer","media":"Stock Track","content":"<p>Day One Biopharmaceuticals Inc. (DAWN) saw its stock soar by 5.04% in pre-market trading on Monday, following the announcement of new data for its lead product candidate, OJEMDA™ (tovorafenib). The company revealed that updated results from its Phase 2 FIREFLY-1 trial will be presented at the upcoming Society for Neuro-Oncology (SNO) Annual Meeting, showcasing the drug's potential in treating pediatric low-grade glioma (pLGG).</p>\n\n<p>The oral presentation, scheduled for November 23, 2025, will feature more than 36 months of follow-up data from the FIREFLY-1 trial. This study evaluates tovorafenib as a once-weekly oral monotherapy in patients aged 6 months to 25 years with relapsed or progressive pLGG harboring a known activating BRAF alteration. The data is expected to demonstrate durable responses and clinical stability off treatment, as well as newly disclosed treatment-free interval information.</p>\n\n<p>Investors are reacting positively to this news, as it suggests OJEMDA's potential efficacy in treating this challenging form of pediatric brain cancer. The durability of responses and the possibility of treatment-free intervals are particularly encouraging, as they could significantly improve the quality of life for young patients. As Day One Biopharmaceuticals continues to advance its pipeline, the market appears optimistic about the company's prospects in the pediatric oncology space.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Day One Biopharmaceuticals Soars 5% on Promising OJEMDA Data for Pediatric Brain Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Day One Biopharmaceuticals Soars 5% on Promising OJEMDA Data for Pediatric Brain Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-10 23:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Day One Biopharmaceuticals Inc. (DAWN) saw its stock soar by 5.04% in pre-market trading on Monday, following the announcement of new data for its lead product candidate, OJEMDA™ (tovorafenib). The company revealed that updated results from its Phase 2 FIREFLY-1 trial will be presented at the upcoming Society for Neuro-Oncology (SNO) Annual Meeting, showcasing the drug's potential in treating pediatric low-grade glioma (pLGG).</p>\n\n<p>The oral presentation, scheduled for November 23, 2025, will feature more than 36 months of follow-up data from the FIREFLY-1 trial. This study evaluates tovorafenib as a once-weekly oral monotherapy in patients aged 6 months to 25 years with relapsed or progressive pLGG harboring a known activating BRAF alteration. The data is expected to demonstrate durable responses and clinical stability off treatment, as well as newly disclosed treatment-free interval information.</p>\n\n<p>Investors are reacting positively to this news, as it suggests OJEMDA's potential efficacy in treating this challenging form of pediatric brain cancer. The durability of responses and the possibility of treatment-free intervals are particularly encouraging, as they could significantly improve the quality of life for young patients. As Day One Biopharmaceuticals continues to advance its pipeline, the market appears optimistic about the company's prospects in the pediatric oncology space.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DAWN","symbol_name":"Day One Biopharmaceuticals Inc.","start_time":0,"source_url":"","article_id":"1141167308","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141167308","pubTimestamp":1762789906,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Day One Biopharmaceuticals Inc. (DAWN) saw its stock soar by 5.04% in pre-market trading on Monday, following the announcement of new data for its lead product candidate, OJEMDA™ (tovorafenib). The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DAWN":"Day One Biopharmaceuticals Inc."},"translate_title":"个股追踪|Day One Biopharmaceuticals飙升5%，因OJEMDA儿科脑癌数据看好","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DAWN":1},"content_text":"Day One Biopharmaceuticals Inc. (DAWN) saw its stock soar by 5.04% in pre-market trading on Monday, following the announcement of new data for its lead product candidate, OJEMDA™ (tovorafenib). The company revealed that updated results from its Phase 2 FIREFLY-1 trial will be presented at the upcoming Society for Neuro-Oncology (SNO) Annual Meeting, showcasing the drug's potential in treating pediatric low-grade glioma (pLGG).\nThe oral presentation, scheduled for November 23, 2025, will feature more than 36 months of follow-up data from the FIREFLY-1 trial. This study evaluates tovorafenib as a once-weekly oral monotherapy in patients aged 6 months to 25 years with relapsed or progressive pLGG harboring a known activating BRAF alteration. The data is expected to demonstrate durable responses and clinical stability off treatment, as well as newly disclosed treatment-free interval information.\nInvestors are reacting positively to this news, as it suggests OJEMDA's potential efficacy in treating this challenging form of pediatric brain cancer. The durability of responses and the possibility of treatment-free intervals are particularly encouraging, as they could significantly improve the quality of life for young patients. As Day One Biopharmaceuticals continues to advance its pipeline, the market appears optimistic about the company's prospects in the pediatric oncology space.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}